Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias Rummel, Wolfram Brugger, Christoph Losem et al.|The Lancet|2013Cited by 1.5k
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Wolfram Brugger, N. Niederle et al.|Blood|2009Cited by 157
A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid LeukemiaE Archimbaud, Dieter Hoelzer, Oliver G. Ottmann et al.|Blood|1999Cited by 119
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Mathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Journal of Clinical Oncology|2017Cited by 83
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Ulrich von Gruenhagen, N. Niederle et al.|Blood|2007Cited by 65